R
Rachel C. Zohar-Kadouch
Researcher at Sheba Medical Center
Publications - 5
Citations - 1100
Rachel C. Zohar-Kadouch is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Clomipramine & Serotonergic. The author has an hindex of 5, co-authored 5 publications receiving 1096 citations.
Papers
More filters
Journal ArticleDOI
Serotonergic Responsivity in Obsessive-Compulsive Disorder: Comparison of Patients and Healthy Controls
TL;DR: Following mCPP, but not following placebo, patients with OCD experienced a transient but marked exacerbation of obsessive-compulsive symptoms, consistent with a special role for the neurotransmitter serotonin in OCD psychopathology.
Journal ArticleDOI
Serotonergic Responsivity in Obsessive-Compulsive Disorder: Effects of Chronic Clomipramine Treatment
TL;DR: Findings are consistent with the development of adaptive subsensitivity to the serotonergic agonist mCPP during clomipramine treatment and suggest a similar alteration in the response to endogenous serotonin may mediate clomIPramine's antiobsessional effects.
Journal ArticleDOI
Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder.
TL;DR: Treatment duration before discontinuation of clomipramine was not related to the frequency or severity of obsessive-compulsive or depressive symptom appearance, suggesting that prolonged drug treatment may be warranted for obsessive-Compulsive disorder.
Journal ArticleDOI
Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder.
Teresa A. Pigott,Joseph Zohar,James L. Hill,Suzanne E. Bernstein,Rachel C. Zohar-Kadouch,Dennis L. Murphy +5 more
TL;DR: Metergoline's ability to block m-CPP's effects on behavior and plasma prolactin lends further support to a serotonergic mediation of m- CPI's effects, including its elicitation of OCD symptoms.
Journal ArticleDOI
Current concepts in the pharmacological treatment of obsessive-compulsive disorder.
TL;DR: Only serotonin reuptake inhibitors, such as clomipramine, fluoxetine and fluvoxamine, are effective in the treatment of both depressed and not depressed OCD patients, and a combination of the 2 therapies is apparently more effective than either modality alone.